Non Interventional Study of the Validation of the Ottawa Score in Cancer Patients With Venous Thromboembolism (VTE)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

420 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-05-31

Study Completion Date

2017-05-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to validate the Ottawa score (risk of thromboembolic recurrences) in cancer patients with thromboembolic disease treated with tinzaparin (Innohep®)

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Long-Term Innohep® Treatment Versus a Vitamin K Antagonist (Warfarin) for the Treatment of Venous Thromboembolism (VTE) in Cancer

NCT01130025

Venous Thromboembolism

COMPLETED PHASE3

Prescription and Utilization of Low Molecular Weight Heparin in Usual Medical Practice for the Curative Treatment of Venous Thromboembolism in Patients With Cancer

NCT01803022

Venous Thromboembolism

COMPLETED

Anti Xa Activity in Cancer Patients Receiving Low-molecular-weight Heparin for Venous Thromboembolism

NCT02898051

Neoplasms Venous Thromboembolism

UNKNOWN

Optimal Duration of Anticoagulation Therapy for Isolated Distal Deep Vein Thrombosis in Patients With Cancer Study

NCT03895502

Venous Thrombosis Neoplasms Anticoagulant

COMPLETED PHASE4

Venous Thromboembolism in Hematologic Malignancy and Hematopoietic Cell Transplant Patients: a Retrospective Study

NCT05396157

Thrombosis, Venous Bleeding Hemorrhage Venous Thromboembolic Disease +2 more

ACTIVE_NOT_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The Ottawa score is a clinical predictive score aiming at stratifying thromboembolic recurrences in cancer patients according to identified clinical risk factors and histological type of the tumor. This score has never been validated externally in a prospective way in patients treated with tinzaparin. The objective of this observational prospective study is to enroll cancer patients with TED treated with tinzaparin for a planned period of 6 months and to collect data on thromboembolic recurrences, major hemorrhages, deaths and heparin-induced thrombocytopenia

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Venous Thromboembolism

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Tinzaparin

Patients with objectively confirmed cancer associated venous thromboembolism receiving tinzaparin treatment to prevent recurrence of venous thromboembolism

Tinzaparin

Intervention Type DRUG

Subcutaneous injection of 175 IU/kg once daily for 6 months

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tinzaparin

Subcutaneous injection of 175 IU/kg once daily for 6 months

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Innohep®

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Cancer patients with histologically confirmed, active or evolving, solid or liquid tumour, or
* Suspected malignant tumour confirmed within a month of index VTE occurrence
* Treated with specific metastatic or adjuvant anti-cancer treatment
* Patients with recent diagnosis of documented symptomatic or incidental VTE and a prescription of tinzaparin for 6 months
* Proximal or distal VTE of lower limbs
* Pulmonary embolism
* Inferior or superior vena cava thrombosis
* Iliac vein thrombosis

Exclusion Criteria

* Skin cancer other than melanoma
* Life expectancy less than 6 months
* Superficial isolated thrombosis
* Isolated subsegmental pulmonary embolism
* Cerebral, visceral thrombosis
* Superior limbs VTE or Central catheter thrombosis
* Patients being treated with anticoagulants by more than 7 days

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No